|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM188536256 |
| 003 |
DE-627 |
| 005 |
20231223182106.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2009 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2009.04.004
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0629.xml
|
| 035 |
|
|
|a (DE-627)NLM188536256
|
| 035 |
|
|
|a (NLM)19443277
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xiao, Jing
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy
|
| 264 |
|
1 |
|c 2009
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.09.2009
|
| 500 |
|
|
|a Date Revised 01.12.2018
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Our recent study suggested that peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist attenuates inflammatory response in activated tubular epithelial cells in IgA nephropathy (IgAN). Here, we explore thiazolidinediones as new therapeutic additives to established treatment regime of renin angiotensin blockade in IgAN. Human proximal tubular epithelial cells (PTEC) were pretreated with PPAR-gamma agonist, rosiglitazone, and/or angiotensin II (AngII) type 1 receptor (ATR1) blocker (ARB), losartan, followed by activation with the conditioned medium collected from human mesangial cells incubated with pIgA1 (IgA-HMC) from patients with IgAN. IgA-HMC conditioned medium up-regulated expression of ICAM-1, IL-6 and ATR1 and activated NF-kappaB and ERK1/2 in PTEC. Dual treatment of rosiglitazone and losartan provided synergistic effect in reducing ICAM-1, IL-6 and ATR1 expression and NF-kappaB and ERK1/2 activation induced by the conditioned media when compared with monotherapy. Our data suggest that rosiglitazone trans-represses AngII signaling and may offer additional potential when combined with ARB in treating IgAN
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a 2-chloro-5-nitrobenzanilide
|2 NLM
|
| 650 |
|
7 |
|a Angiotensin II Type 1 Receptor Blockers
|2 NLM
|
| 650 |
|
7 |
|a Anilides
|2 NLM
|
| 650 |
|
7 |
|a Culture Media, Conditioned
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin A
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-6
|2 NLM
|
| 650 |
|
7 |
|a NF-kappa B
|2 NLM
|
| 650 |
|
7 |
|a PPAR gamma
|2 NLM
|
| 650 |
|
7 |
|a Receptor, Angiotensin, Type 1
|2 NLM
|
| 650 |
|
7 |
|a Thiazolidinediones
|2 NLM
|
| 650 |
|
7 |
|a Rosiglitazone
|2 NLM
|
| 650 |
|
7 |
|a 05V02F2KDG
|2 NLM
|
| 650 |
|
7 |
|a Intercellular Adhesion Molecule-1
|2 NLM
|
| 650 |
|
7 |
|a 126547-89-5
|2 NLM
|
| 650 |
|
7 |
|a Extracellular Signal-Regulated MAP Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.24
|2 NLM
|
| 650 |
|
7 |
|a Losartan
|2 NLM
|
| 650 |
|
7 |
|a JMS50MPO89
|2 NLM
|
| 700 |
1 |
|
|a Leung, Joseph C K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chan, Loretta Y Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, Sydney C W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lai, Kar Neng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 132(2009), 2 vom: 17. Aug., Seite 266-76
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:132
|g year:2009
|g number:2
|g day:17
|g month:08
|g pages:266-76
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2009.04.004
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 132
|j 2009
|e 2
|b 17
|c 08
|h 266-76
|